Europe’s Biosimilars Ahead Of U.S., But Still Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Beware confusion with generics, Biosimilars 2000 speakers warn.
You may also be interested in...
G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.
Sandoz Hones Biosimilars Strategy
Novartis generics unit pursues two different approaches for the human growth hormone Omnitrope and the epoetin alfa follow-on Binocrit.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.